Exclusive special offer and discount title banner vector image

GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET FORECAST 2024-2032

SCOPE OF THE REPORT

Global Artificial Intelligence (AI) in Epidemiology Market by Deployment (on-premise, Web-based, Cloud-based) Market by Application (Infection Prediction & Forecasting, Disease & Syndromic Surveillance, Monitoring Population Health & Incidence/ Prevalence) Market by End Use (Government & State Agencies, Research Labs, Pharmaceutical & Biotechnology Companies, Healthcare Providers) by Geography


MARKET OVERVIEW

In terms of revenue, the global artificial intelligence (AI) in epidemiology market was valued at $xx million in 2023 and is expected to reach $xx million by 2032, growing at a CAGR of 27.33% during the forecast period 2024-2032

Epidemiology is the branch of medical science that focuses on the study of patterns, causes, and effects of health-related events and diseases within populations. It encompasses the investigation of various factors, such as the distribution and determinants of diseases, their prevalence, risk factors, and outcomes. 

Epidemiologists use a range of research methods, including observational studies, cohort studies, and clinical trials, to gather and analyze data in order to understand the underlying factors influencing health and disease in populations. 

With the emergence of artificial intelligence (AI), there has been a paradigm shift in the field of epidemiology. AI in epidemiology refers to the application of AI technologies, including machine learning algorithms, data mining techniques, and predictive analytics, to analyze large-scale epidemiological data, identify patterns, predict disease outbreaks, and inform public health interventions.

Artificial Intelligence (AI) In Epidemiology Market

GROWTH ENABLERS

Key growth enablers of the global artificial intelligence (AI) in epidemiology market:

  • Early detection and surveillance of disease outbreaks
  • Predictive modeling to forecast disease trends
    • Predictive modeling leverages AI algorithms, such as machine learning and deep learning, to analyze large-scale healthcare datasets and develop forecasting models for disease incidence, prevalence, and transmission.
    • By utilizing historical data on disease outbreaks, environmental factors, population demographics, and healthcare utilization patterns, predictive modeling can forecast future disease trends, assess the impact of interventions, and guide decision-making for public health planning and resource allocation. This capability is particularly valuable for epidemiologists and public health officials.
    • Additionally, predictive modeling and forecasting provide valuable insights for policymakers, healthcare providers, and other stakeholders, enabling them to make informed decisions to improve public health outcomes.
  • Data availability for epidemiological research

GROWTH RESTRAINTS

Key growth restraining factors of the global artificial intelligence (AI) in epidemiology market:

  • Privacy and ethical concerns regarding sensitive patient data
  • Data quality and availability challenges 
    • Epidemiological data frequently originates from diverse sources utilizing different collection methods. However, it results in potential gaps, inconsistencies, and inaccuracies that impede the reliability of AI analysis. 
    • Data collection processes may inadvertently favor specific demographics or locations, introducing biases into the data. AI models trained on such biased data can perpetuate these biases, resulting in potentially misleading outcomes.
    • As a result, the lack of standardized data collection and reporting practices across regions and healthcare systems creates challenges in building generalizable AI models.

To Know More About This Report, Request a Free Sample Copy

KEY MARKET TRENDS

Global Artificial Intelligence (AI) in Epidemiology Market | Top Trends

  • The swift progress in machine learning algorithms and data analytics techniques is facilitating the development of increasingly intricate epidemiological modeling, predictive analytics, and outbreak detection methods. Utilizing AI-driven methodologies, analysts are increasingly scrutinizing extensive healthcare datasets, genomic sequences, environmental variables, and social media streams to discern trends, anticipate disease outbreaks, and provide insights for public health strategies.
  • The expansion of telehealth and remote monitoring has surged due to the COVID-19 pandemic. This prompts an increased demand for AI-enhanced solutions tailored to virtual care delivery and remote patient surveillance.

 

MARKET SEGMENTATION

Market Segmentation – Deployment, Application, and End Use – 

Market by Deployment: 

  • On-Premise
  • Web-Based
  • Cloud-Based
    • The cloud-based segment, under the deployment category, is set to grow with a prominent CAGR of xx% between 2024 to 2032. 
    • Cloud platforms offer unparalleled accessibility to AI tools and resources, allowing organizations of all sizes to leverage sophisticated analytics capabilities without the need for substantial investments in hardware or IT infrastructure. 
    • This accessibility democratizes access to AI-driven epidemiological solutions, enabling public health agencies, research institutions, and healthcare organizations to harness the power of data-driven insights to combat infectious diseases effectively.
    • Moreover, cloud-based deployments offer significant advantages in terms of speed and agility. Compared to traditional on-premise setups, cloud-based AI solutions can be implemented much more quickly, enabling organizations to deploy and scale epidemiological models and analytics rapidly.

Market by Application:

  • Infection Prediction & Forecasting
    • Infection prediction & forecasting is anticipated to be a significant application in the global market during the forecast period, 2024 to 2032.
    • With the increasing globalization and interconnectedness of populations, coupled with factors such as urbanization, climate change, and encroachment into natural habitats, the risk of emerging infectious diseases has heightened. 
    • AI-powered solutions offer advanced capabilities for analyzing complex datasets, identifying patterns, and predicting disease outbreaks with greater accuracy and speed than traditional methods.
    • Machine learning (ML) algorithms can leverage various data sources, including clinical data, genomic sequences, environmental factors, social media feeds, and mobility patterns, to detect early warning signs of infectious diseases, track their spread, and forecast their trajectory.
  • Disease & Syndromic Surveillance
  • Monitoring Population Health & Incidence/Prevalence

Market by End Use:

  • Government & State Agencies
  • Research Labs
  • Pharmaceutical & Biotechnology Companies
  • Healthcare Providers

GEOGRAPHICAL STUDY

Geographical Study Based on Four Major Regions: 

  • North America: The United States and Canada
    • North America benefits from a well-developed healthcare infrastructure characterized by advanced systems like electronic health records (EHRs) and robust data infrastructure, facilitating seamless integration and utilization of AI solutions.
    • The Government Accountability Office (GAO) and the National Academy of Medicine (NAM) have jointly embarked on an initiative to delve into the application of AI/ML in healthcare, evaluate its implications, and pinpoint essential strategies for maximizing its utilization. This concerted effort serves as a catalyst for driving advancements in AI within the epidemiology market in North America.
    • Furthermore, the presence of key players such as Google, IBM, and Microsoft, actively contribute to the advancement of AI solutions for various industries, including healthcare and epidemiology.
  • Europe: The United Kingdom, France, Germany, Spain, Italy, and Rest of Europe
  • Asia-Pacific: China, Japan, India, South Korea, Australia & New Zealand, and Rest of Asia-Pacific
  • Rest of World: Latin America, the Middle East & Africa

 

MAJOR PLAYERS

Major players in the global artificial intelligence (AI) in epidemiology market:

  • Cerner Corporation
  • Cognizant
  • eClinical Works Inc
  • Alphabet Inc
  • Intel Corporation

Key strategies adopted by some of these companies:

  • In September 2023, Oracle launched an addition to its Cerner electronic medical record system, integrating generative AI services. By integrating AI and conversational voice technology, Oracle aims to empower healthcare providers with advanced capabilities. This includes automating medical note-taking, facilitating medication orders, and enabling seamless access to lab reviews.
  • In May 2023, Siemens Healthineers and CommonSpirit Health reached an agreement to acquire Block Imaging.

REPORT SYNOPSIS

REPORT SCOPEDETAILS
Market Forecast Years2024-2032
Base Year2023
Market Historical Years2018-2022
Forecast Units

Revenue ($ Million)

Segments AnalyzedDeployment, Application, and End Use
Geographies AnalyzedNorth America, Europe, Asia-Pacific, and Rest of World
Companies AnalyzedCerner Corporation, Cognizant, eClinical Works Inc, Alphabet Inc, Intel Corporation, Epic Systems Corporation, Microsoft Corporation, Meditech, Komodo Health, Siemens Healthineers, Bayer Healthcare, SAS Institute, Cardiolyse, Predixion Healthcare (Jvion LLC)
TABLE OF CONTENTS
  1. RESEARCH SCOPE & METHODOLOGY
    1. STUDY OBJECTIVES
    2. METHODOLOGY
    3. ASSUMPTIONS & LIMITATIONS
  2. EXECUTIVE SUMMARY
    1. MARKET SIZE & ESTIMATES
    2. MARKET OVERVIEW
    3. SCOPE OF STUDY
    4. CRISIS SCENARIO ANALYSIS
      1. IMPACT OF COVID-19 ON ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET
    5. MAJOR MARKET FINDINGS
      1. PUBLIC-PRIVATE PARTNERSHIP IN AI FOR HEALTH INFECTION PREDICTION & FORECASTING
      2. RISING APPLICATIONS OF AI IN PERSONALIZED MEDICATIONS
      3. INCREASING POPULARITY IN INFECTION PREDICTION AND FORECASTING ON CLOUD-BASED PLATFORMS
  3. MARKET DYNAMICS
    1. KEY DRIVERS
      1. EARLY DETECTION AND SURVEILLANCE OF DISEASE OUTBREAKS
      2. PREDICTIVE MODELING TO FORECAST DISEASE TRENDS
      3. DATA AVAILABILITY FOR EPIDEMIOLOGICAL RESEARCH
    2. KEY RESTRAINTS
      1. PRIVACY AND ETHICAL CONCERNS REGARDING SENSITIVE PATIENT DATA
      2. DATA QUALITY AND AVAILABILITY CHALLENGES 
  4. KEY ANALYTICS
    1. KEY MARKET TRENDS
      1. ADVANCEMENTS IN MACHINE LEARNING AND DATA ANALYTICS
      2. EXPANSION OF TELEHEALTH AND REMOTE MONITORING
      3. INTEGRATION OF AI IN PUBLIC HEALTH SYSTEMS
    2. PORTER’S FIVE FORCES ANALYSIS
      1. BUYERS POWER
      2. SUPPLIERS POWER
      3. SUBSTITUTES
      4. NEW ENTRANTS
      5. INDUSTRY RIVALRY
    3. GROWTH PROSPECT MAPPING
    4. MARKET MATURITY ANALYSIS
    5. MARKET CONCENTRATION ANALYSIS
  5. MARKET BY DEPLOYMENT
    1. ON-PREMISE
      1. MARKET FORECAST FIGURE
      2. SEGMENT ANALYSIS
    2. WEB-BASED
      1. MARKET FORECAST FIGURE
      2. SEGMENT ANALYSIS
    3. CLOUD-BASED
      1. MARKET FORECAST FIGURE
      2. SEGMENT ANALYSIS
  6. MARKET BY APPLICATION
    1. INFECTION PREDICTION & FORECASTING
      1. MARKET FORECAST FIGURE
      2. SEGMENT ANALYSIS
    2. DISEASE & SYNDROMIC SURVEILLANCE
      1. MARKET FORECAST FIGURE
      2. SEGMENT ANALYSIS
    3. MONITORING POPULATION HEALTH & INCIDENCE/ PREVALENCE
      1. MARKET FORECAST FIGURE
      2. SEGMENT ANALYSIS
  7. MARKET BY END USE
    1. GOVERNMENT & STATE AGENCIES
      1. MARKET FORECAST FIGURE
      2. SEGMENT ANALYSIS
    2. RESEARCH LABS
      1. MARKET FORECAST FIGURE
      2. SEGMENT ANALYSIS
    3. PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
      1. MARKET FORECAST FIGURE
      2. SEGMENT ANALYSIS
    4. HEALTHCARE PROVIDERS
      1. MARKET FORECAST FIGURE
      2. SEGMENT ANALYSIS
  8. GEOGRAPHICAL ANALYSIS
    1. NORTH AMERICA
      1. MARKET SIZE & ESTIMATES
      2. NORTH AMERICA ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET DRIVERS
      3. NORTH AMERICA ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET CHALLENGES
      4. KEY PLAYERS IN NORTH AMERICA ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET
      5. COUNTRY ANALYSIS
        1. UNITED STATES
          1. UNITED STATES ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET SIZE & OPPORTUNITIES
        2. CANADA
          1. CANADA ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET SIZE & OPPORTUNITIES
    2. EUROPE
      1. MARKET SIZE & ESTIMATES
      2. EUROPE ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET DRIVERS
      3. EUROPE ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET CHALLENGES
      4. KEY PLAYERS IN EUROPE ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET
      5. COUNTRY ANALYSIS
        1. UNITED KINGDOM
          1. UNITED KINGDOM ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET SIZE & OPPORTUNITIES
        2. GERMANY
          1. GERMANY ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET SIZE & OPPORTUNITIES
        3. FRANCE
          1. FRANCE ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET SIZE & OPPORTUNITIES
        4. ITALY
          1. ITALY ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET SIZE & OPPORTUNITIES
        5. SPAIN
          1. SPAIN ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET SIZE & OPPORTUNITIES
        6. REST OF EUROPE
          1. REST OF EUROPE ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET SIZE & OPPORTUNITIES
    3. ASIA-PACIFIC
      1. MARKET SIZE & ESTIMATES
      2. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET DRIVERS
      3. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET CHALLENGES
      4. KEY PLAYERS IN ASIA-PACIFIC ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET
      5. COUNTRY ANALYSIS
        1. CHINA
          1. CHINA ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET SIZE & OPPORTUNITIES
        2. JAPAN
          1. JAPAN ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET SIZE & OPPORTUNITIES
        3. INDIA
          1. INDIA ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET SIZE & OPPORTUNITIES
        4. SOUTH KOREA
          1. SOUTH KOREA ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET SIZE & OPPORTUNITIES
        5. AUSTRALIA & NEW ZEALAND
          1. AUSTRALIA & NEW ZEALAND ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET SIZE & OPPORTUNITIES
        6. REST OF ASIA-PACIFIC
          1. REST OF ASIA-PACIFIC ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET SIZE & OPPORTUNITIES
    4. REST OF WORLD
      1. MARKET SIZE & ESTIMATES
      2. REST OF WORLD ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET DRIVERS
      3. REST OF WORLD ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET CHALLENGES
      4. KEY PLAYERS IN REST OF WORLD ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET
      5. REGIONAL ANALYSIS
        1. LATIN AMERICA
          1. LATIN AMERICA ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET SIZE & OPPORTUNITIES
        2. MIDDLE EAST & AFRICA
          1. MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET SIZE & OPPORTUNITIES
  9. COMPETITIVE LANDSCAPE
    1. KEY STRATEGIC DEVELOPMENTS
      1. MERGERS & ACQUISITIONS
      2. PRODUCT LAUNCHES & DEVELOPMENTS
      3. PARTNERSHIPS & AGREEMENTS
      4. BUSINESS EXPANSIONS & DIVESTITURES
    2. COMPANY PROFILES
      1. ALPHABET INC
        1. COMPANY OVERVIEW
        2. PRODUCT LIST
        3. STRENGTHS & CHALLENGES
      2. BAYER HEALTHCARE
        1. COMPANY OVERVIEW
        2. PRODUCT LIST
        3. STRENGTHS & CHALLENGES
      3. CARDIOLYSE
        1. COMPANY OVERVIEW
        2. PRODUCT LIST
        3. STRENGTHS & CHALLENGES
      4. CERNER CORPORATION
        1. COMPANY OVERVIEW
        2. PRODUCT LIST
        3. STRENGTHS & CHALLENGES
      5. COGNIZANT
        1. COMPANY OVERVIEW
        2. PRODUCT LIST
        3. STRENGTHS & CHALLENGES
      6. ECLINICAL WORKS INC
        1. COMPANY OVERVIEW
        2. PRODUCT LIST
        3. STRENGTHS & CHALLENGES
      7. EPIC SYSTEMS CORPORATION
        1. COMPANY OVERVIEW
        2. PRODUCT LIST
        3. STRENGTHS & CHALLENGES
      8. INTEL CORPORATION
        1. COMPANY OVERVIEW
        2. PRODUCT LIST
        3. STRENGTHS & CHALLENGES
      9. KOMODO HEALTH
        1. COMPANY OVERVIEW
        2. PRODUCT LIST
        3. STRENGTHS & CHALLENGES
      10. MEDITECH
        1. COMPANY OVERVIEW
        2. PRODUCT LIST
        3. STRENGTHS & CHALLENGES
      11. MICROSOFT CORPORATION
        1. COMPANY OVERVIEW
        2. PRODUCT LIST
        3. STRENGTHS & CHALLENGES
      12. PREDIXION HEALTHCARE (JVION LLC)
        1. COMPANY OVERVIEW
        2. PRODUCT LIST
        3. STRENGTHS & CHALLENGES
      13. SAS INSTITUTE
        1. COMPANY OVERVIEW
        2. PRODUCT LIST
        3. STRENGTHS & CHALLENGES
      14. SIEMENS HEALTHINEERS
        1. COMPANY OVERVIEW
        2. PRODUCT LIST
        3. STRENGTHS & CHALLENGES

LIST OF TABLES

TABLE 1: MARKET SNAPSHOT — ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY

TABLE 2: GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, BY DEPLOYMENT, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 3: GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, BY DEPLOYMENT, FORECAST YEARS, 2024-2032 (IN $ MILLION)

TABLE 4: GLOBAL ON-PREMISE MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 5: GLOBAL ON-PREMISE MARKET, BY REGION, FORECAST YEARS, 2024-2032 (IN $ MILLION)

TABLE 6: GLOBAL WEB-BASED MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 7: GLOBAL WEB-BASED MARKET, BY REGION, FORECAST YEARS, 2024-2032 (IN $ MILLION)

TABLE 8: GLOBAL CLOUD-BASED MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 9: GLOBAL CLOUD-BASED MARKET, BY REGION, FORECAST YEARS, 2024-2032 (IN $ MILLION)

TABLE 10: GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, BY APPLICATION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 11: GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, BY APPLICATION, FORECAST YEARS, 2024-2032 (IN $ MILLION)

TABLE 12: GLOBAL INFECTION PREDICTION & FORECASTING MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 13: GLOBAL INFECTION PREDICTION & FORECASTING MARKET, BY REGION, FORECAST YEARS, 2024-2032 (IN $ MILLION)

TABLE 14: GLOBAL DISEASE & SYNDROMIC SURVEILLANCE MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 15: GLOBAL DISEASE & SYNDROMIC SURVEILLANCE MARKET, BY REGION, FORECAST YEARS, 2024-2032 (IN $ MILLION)

TABLE 16: GLOBAL MONITORING POPULATION HEALTH & INCIDENCE/ PREVALENCE MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 17: GLOBAL MONITORING POPULATION HEALTH & INCIDENCE/ PREVALENCE MARKET, BY REGION, FORECAST YEARS, 2024-2032 (IN $ MILLION)

TABLE 18: GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, BY END USE, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 19: GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, BY END USE, FORECAST YEARS, 2024-2032 (IN $ MILLION)

TABLE 20: GLOBAL GOVERNMENT & STATE AGENCIES MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 21: GLOBAL GOVERNMENT & STATE AGENCIES MARKET, BY REGION, FORECAST YEARS, 2024-2032 (IN $ MILLION)

TABLE 22: GLOBAL RESEARCH LABS MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 23: GLOBAL RESEARCH LABS MARKET, BY REGION, FORECAST YEARS, 2024-2032 (IN $ MILLION)

TABLE 24: GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 25: GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET, BY REGION, FORECAST YEARS, 2024-2032 (IN $ MILLION)

TABLE 26: GLOBAL HEALTHCARE PROVIDERS MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 27: GLOBAL HEALTHCARE PROVIDERS MARKET, BY REGION, FORECAST YEARS, 2024-2032 (IN $ MILLION)

TABLE 28: GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, BY GEOGRAPHY, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 29: GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, BY GEOGRAPHY, FORECAST YEARS, 2024-2032 (IN $ MILLION)

TABLE 30: NORTH AMERICA ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 31: NORTH AMERICA ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, BY COUNTRY, FORECAST YEARS, 2024-2032 (IN $ MILLION)

TABLE 32: KEY PLAYERS OPERATING IN NORTH AMERICA ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET

TABLE 33: EUROPE ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 34: EUROPE ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, BY COUNTRY, FORECAST YEARS, 2024-2032 (IN $ MILLION)

TABLE 35: KEY PLAYERS OPERATING IN EUROPE ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET

TABLE 36: ASIA-PACIFIC ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 37: ASIA-PACIFIC ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, BY COUNTRY, FORECAST YEARS, 2024-2032 (IN $ MILLION)

TABLE 38: KEY PLAYERS OPERATING IN ASIA-PACIFIC ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET

TABLE 39: REST OF WORLD ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 40: REST OF WORLD ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, BY REGION, FORECAST YEARS, 2024-2032 (IN $ MILLION)

TABLE 41: KEY PLAYERS OPERATING IN REST OF WORLD ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET

TABLE 42: LIST OF MERGERS & ACQUISITIONS

TABLE 43: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS

TABLE 44: LIST OF PARTNERSHIPS & AGREEMENTS

TABLE 45: LIST OF BUSINESS EXPANSIONS & DIVESTITURES

 

LIST OF FIGURES

FIGURE 1: KEY MARKET TRENDS

FIGURE 2: PORTER’S FIVE FORCES ANALYSIS

FIGURE 3: GROWTH PROSPECT MAPPING 

FIGURE 4: MARKET MATURITY ANALYSIS

FIGURE 5: MARKET CONCENTRATION ANALYSIS

FIGURE 6: GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, GROWTH POTENTIAL, BY DEPLOYMENT, IN 2023

FIGURE 7: GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, BY ON-PREMISE, 2024-2032 (IN $ MILLION)

FIGURE 8: GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, BY WEB-BASED, 2024-2032 (IN $ MILLION)

FIGURE 9: GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, BY CLOUD-BASED, 2024-2032 (IN $ MILLION)

FIGURE 10: GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, GROWTH POTENTIAL, BY APPLICATION, IN 2023

FIGURE 11: GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, BY INFECTION PREDICTION & FORECASTING, 2024-2032 (IN $ MILLION)

FIGURE 12: GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, BY DISEASE & SYNDROMIC SURVEILLANCE, 2024-2032 (IN $ MILLION)

FIGURE 13: GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, BY MONITORING POPULATION HEALTH & INCIDENCE/ PREVALENCE, 2024-2032 (IN $ MILLION)

FIGURE 14: GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, GROWTH POTENTIAL, BY END USE, IN 2023

FIGURE 15: GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, BY GOVERNMENT & STATE AGENCIES, 2024-2032 (IN $ MILLION)

FIGURE 16: GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, BY RESEARCH LABS, 2024-2032 (IN $ MILLION)

FIGURE 17: GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2024-2032 (IN $ MILLION)

FIGURE 18: GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, BY HEALTHCARE PROVIDERS, 2024-2032 (IN $ MILLION)

FIGURE 19: NORTH AMERICA ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, COUNTRY OUTLOOK, 2023 & 2032 (IN %)

FIGURE 20: UNITED STATES ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, 2024-2032 (IN $ MILLION)

FIGURE 21: CANADA ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, 2024-2032 (IN $ MILLION)

FIGURE 22: EUROPE ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, COUNTRY OUTLOOK, 2023 & 2032 (IN %)

FIGURE 23: UNITED KINGDOM ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, 2024-2032 (IN $ MILLION)

FIGURE 24: GERMANY ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, 2024-2032 (IN $ MILLION)

FIGURE 25: FRANCE ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, 2024-2032 (IN $ MILLION)

FIGURE 26: ITALY ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, 2024-2032 (IN $ MILLION)

FIGURE 27: SPAIN ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, 2024-2032 (IN $ MILLION)

FIGURE 28: REST OF EUROPE ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, 2024-2032 (IN $ MILLION)

FIGURE 29: ASIA-PACIFIC ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, COUNTRY OUTLOOK, 2023 & 2032 (IN %)

FIGURE 30: CHINA ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, 2024-2032 (IN $ MILLION)

FIGURE 31: JAPAN ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, 2024-2032 (IN $ MILLION)

FIGURE 32: INDIA ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, 2024-2032 (IN $ MILLION)

FIGURE 33: SOUTH KOREA ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, 2024-2032 (IN $ MILLION)

FIGURE 34: AUSTRALIA & NEW ZEALAND ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, 2024-2032 (IN $ MILLION)

FIGURE 35: REST OF ASIA-PACIFIC ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, 2024-2032 (IN $ MILLION)

FIGURE 36: REST OF WORLD ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, REGIONAL OUTLOOK, 2023 & 2032 (IN %)

FIGURE 37: LATIN AMERICA ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, 2024-2032 (IN $ MILLION)

FIGURE 38: MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE (AI) IN EPIDEMIOLOGY MARKET, 2024-2032 (IN $ MILLION)

FAQ’s

FAQs

AI algorithms can analyze real-time healthcare data to detect anomalies, identify clusters of disease cases, and predict disease outbreaks before they occur. This early warning system enables public health authorities to implement timely interventions and mitigate the spread of infectious diseases.

AI is being utilized in various ways to combat infectious diseases like COVID-19, including contact tracing, vaccine development, drug repurposing, diagnostic testing, and epidemiological modeling. AI-driven approaches accelerate research efforts and inform public health strategies to control the spread of infectious diseases.

Yes, AI can be used to develop personalized healthcare interventions based on individual patient data, genetic factors, lifestyle behaviors, and environmental exposures. This approach, known as precision public health, enables targeted interventions to improve health outcomes and prevent disease.